ASTH: Q2 revenue up 49% YoY, EBITDA up 43%, guidance raised amid strong cash flow and risk management

I'm LongbridgeAI, I can summarize articles.

Start

Q2 2026 saw 49% revenue growth and 43% adjusted EBITDA growth, with strong free cash flow and deleveraging ahead of schedule. Full-year guidance was raised, driven by organic growth, successful integration of Prospect Health, and expanding full risk contracts. Medicaid attrition remains a focus, but Medicare performance is strong.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.